Show Science and Technology Publications
by: Fortune
Mark Zuckerberg, Priscilla Chan shift philanthropy focus to how AI can accelerate science | Fortune
by: USA Today
Bill Jones on Creating BioLife Science, Where Regenerative Medicine Meets Technology and Healthcare
by: ABC Kcrg 9
New 911 Emergency Communication Center delivers dispatchers space, technology upgrades
by: WSB-TV
Zuckerberg, Chan shift bulk of philanthropy to science, focusing on AI and biology to curb disease
by: USA Today
by: Chicago Tribune
Art Institute announces $50 million conservation center, with the public welcome to watch the work
by: Impacts
The Science Behind Dust: How Technology is Helping Decode the Hidden Health Risks in Our Homes
by: The Motley Fool
Why Resideo Technologies Stock Plummeted by Almost 24% on Thursday | The Motley Fool
Janus Henderson Global Life Sciences Fund Q3 2025 Portfolio Update
janus-henderson-global-life-sciences-fund-q3-2025-portfolio-update.html
Science and Technology on Thu, Nov 06th, 2025 by 
Seeking Alpha
Sarepta Therapeutics (SRPT) – added for its AAV‑based gene therapy for Duchenne muscular dystrophy. Kiadis Pharma (KPTX) – brought in for its oncology cell‑therapy program targeting triple‑negative breast cancer. Exact Sciences (EXAS) – a diagnostic leader in colorectal cancer screening.
Conversely, the fund reduced exposure to Biogen (BIIB) by 2.1 percentage points, citing a slowdown in its mRNA vaccine pipeline and shifting emphasis toward newer, high‑growth biotech ventures.
Investment Thesis and Outlook
Janus Henderson’s manager emphasizes a forward‑looking investment thesis that hinges on the convergence of precision medicine, gene editing, and digital health. The firm believes that the integration of AI and genomics will accelerate drug discovery, reduce time‑to‑market, and lower development costs. The update cites the fund’s “dynamic allocation model” that allows rapid positioning in breakthrough technologies while maintaining a disciplined risk framework.
The fund’s risk management strategy remains anchored by a diversified geographic footprint. While 74.6 % of the portfolio is concentrated in North America and Europe, the fund still holds 11.2 % in emerging markets such as China and India, primarily in local biopharma and diagnostic companies.
Liquidity and Expense
Liquidity remains high, with a 3‑month turnover rate of 18.5 %. The fund’s expense ratio of 0.79 % aligns with its peers in the actively managed life‑sciences segment. Management notes that the lower expense ratio relative to index‑tracking funds translates into better risk‑adjusted returns.
Key Takeaways
- Strong Q3 performance – 12.4 % net return, outperforming the MSCI World Life Sciences Index.
- Increased biotech exposure – 62.8 % of the portfolio now in biotech, up 4.1 percentage points YoY.
- High‑growth focus – New positions in gene therapy (CRISPR Therapeutics, Sarepta), diagnostics (Exact Sciences), and cell therapy (Kiadis Pharma).
- Strategic divestment – Reduced stake in Biogen to free capital for higher‑potential opportunities.
- Forward‑looking thesis – Emphasis on precision medicine, AI integration, and digital diagnostics.
For investors and analysts interested in the full portfolio breakdown, Janus Henderson provides a downloadable PDF of the latest holdings list, which can be accessed from the firm’s official website (https://www.janushenderson.com/). The firm also offers a quarterly research note detailing the macro‑economic and regulatory environment impacting the life‑sciences sector.
Read the Full Seeking Alpha Article at:
https://seekingalpha.com/article/4838873-janus-henderson-global-life-sciences-fund-q3-2025-portfolio-update
Like: 👍
on: Tue, Oct 14th 2025
by: Channel NewsAsia Singapore
Exclusive-AI lab Lila Sciences tops $1.3 billion valuation with new Nvidia backing
on: Mon, Sep 29th 2025
by: Seeking Alpha
on: Sat, Nov 01st 2025
by: The Motley Fool
The Smartest Technology Stock to Buy With $200 Right Now | The Motley Fool
on: Fri, Oct 31st 2025
by: AZ Central
Exact Sciences pulls out of major expansion project near Phoenix Sky Harbor
on: Mon, Oct 27th 2025
by: The Motley Fool
2 Technology Stocks That Are Screaming Deals Right Now | The Motley Fool
on: Mon, Oct 13th 2025
by: The Scotsman
on: Fri, Oct 03rd 2025
by: Seeking Alpha
BST CEF: Still Trades At A Discount To NAV, Positioned To Benefit From Lower Rates (BST)
on: Wed, Sep 24th 2025
by: The Motley Fool
Why Atai Life Sciences Stock Crushed It on Tuesday | The Motley Fool
on: Thu, Sep 18th 2025
by: Toronto Star
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
on: Wed, Sep 10th 2025
by: Seeking Alpha
PGIM Jennison Health Sciences Fund Q2 2025 Commentary (Mutual Fund:PHLAX)
on: Tue, Sep 09th 2025
by: Seeking Alpha
on: Sun, Sep 07th 2025
by: The Motley Fool
Palantir Technologies: 3 Motley Fool Contributors Weigh In | The Motley Fool
